Repurposed Drugs: EU Pharma Reform Offers Boost, But Payers ‘Must Recognize Health Gains’

 
• By Eliza Slawther
  
Payers need to ‘recognize the wider health gain and improved patient outcomes’ achieved by repurposing drugs (Shutterstock)

More from Review Pathways

More from Pathways & Standards